Repligen RGEN
NASDAQ RGEN
$164.68 -0.37 (-0.22%)
As of: Sep 10, 2026 · 3:59 PM EDT

Repligen (RGEN) Restructuring Costs (2012 - 2026)

Repligen's (RGEN) quarterly Restructuring Costs came in at $2.7 million in Q2 2026, up 25.72% year-over-year from $2.2 million in Q2 2025, and up 81.68% quarter-over-quarter from $1.5 million in Q1 2026.

Analysis

Repligen (RGEN) Restructuring Costs (2012 - 2026) Analysis & Trends

Repligen (RGEN) has reported Restructuring Costs for 5 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Restructuring Costs rose 25.72% year-over-year to $2.7 million in Q2 2026; TTM through Jun 2026 was $8.3 million, a 37.09% increase from a year earlier, with the FY2014 full-year figure at $1.9 million, up 2032.89% from the prior year.
  • Restructuring Costs was $2.7 million for Q2 2026 at Repligen, up from $1.5 million in the prior quarter.
  • Over five years, Restructuring Costs peaked at $2.7 million in Q2 2026 and troughed at $1.5 million in Q1 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 223.99 Bn 219.93 Bn 8.34 Bn
2 Danaher 141.56 Bn 137.22 Bn 3.61 Bn
3 Agilent Technologies 40.36 Bn 38.60 Bn 1.04 Bn
4 Illumina 30.41 Bn 29.24 Bn 770.00 Mn
5 Revvity 13.50 Bn 12.48 Bn 416.87 Mn
6 Bio-Techne 11.25 Bn 10.98 Bn 211.39 Mn
7 Bio-Rad Laboratories 9.88 Bn 8.26 Bn 345.80 Mn
8 Repligen 9.29 Bn 8.28 Bn 110.04 Mn
9 10x Genomics 8.62 Bn 8.06 Bn 112.50 Mn
10 Bruker 8.16 Bn 7.94 Bn 416.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.72 Mn
Mar 31, 2026 1.50 Mn
Jun 30, 2025 2.16 Mn
Mar 31, 2025 1.97 Mn
Dec 31, 2014 1.95 Mn
Sep 30, 2014 10,000.00
Jun 30, 2014 18,000.00
Mar 31, 2014 98,000.00
Dec 31, 2013 45,000.00
Sep 30, 2013 65,000.00
Jun 30, 2013 35,000.00
Mar 31, 2013 -54,000.00
Dec 31, 2012 267,000.00
Sep 30, 2012 344,000.00